SG11201900400QA - Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 - Google Patents

Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Info

Publication number
SG11201900400QA
SG11201900400QA SG11201900400QA SG11201900400QA SG11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA SG 11201900400Q A SG11201900400Q A SG 11201900400QA
Authority
SG
Singapore
Prior art keywords
sanofi
main
frankfurt
deutschland gmbh
international
Prior art date
Application number
SG11201900400QA
Inventor
Jana Albrecht
Christian Beil
Jochen Beninga
Katja Kroll
Christian Lange
Wulf Dirk Leuschner
Ercole Rao
Marion Schneider
Peter Wonerow
Stéphane Guerif
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201900400QA publication Critical patent/SG11201900400QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1#11101111 0 11101 HOE 3E1 0 01111113 10111001110110111011011# International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/015340 Al 25 January 2018 (25.01.2018) WIP0 I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) FRANKFURT AM MAIN (DE). KROLL, Katja; c/ o sanofi-aventis Deutschland GmbH, 65926 FRANK- A61K 39/395 (2006.01) FURT AM MAIN (DE). LANGE, Christian; c/o sanofi- (21) International Application Number: aventis Deutschland GmbH, 65926 FRANKFURT AM MAIN (DE). LEUSCHNER, Wulf Dirk; c/o sanofi-aven- PCT/EP2017/068020 tis Deutschland GmbH, 65926 FRANKFURT AM MAIN (22) International Filing Date: (DE). RAO, Ercole; c/o sanofi-aventis Deutschland GmbH, 17 July 2017 (17.07.2017) 65926 FRANKFURT AM MAIN (DE). SCHNEIDER, Marion; c/o sanofi-aventis Deutschland GmbH, 65926 (25) Filing Language: English FRANKFURT AM MAIN (DE). WONEROW, Peter; c/ (26) Publication Language: English o sanofi-aventis Deutschland GmbH, 65926 FRANKFURT (30) Priority Data: AM MAIN (DE). GUERIF, Stephane; c/o Sanofi, Patent 16305923.1 18 July 2016 (18.07.2016) EP Department, 54 me la Boetie, 75008 Paris (FR). (74) Agent: TINEL, Marie-Line; c/o Sanofi, Patent Depart- (71) Applicant: SANOFI [FR/FR]; 54 me La Boetie, 75008 PARIS (FR). ment, 54 me La Boetie, 75008 PARIS (FR). (81) Designated States (unless otherwise indicated, for every (72) Inventors: ALBRECHT, Jana; c/o sanofi-aventis kind of national protection available): AE, AG, AL, AM, Deutschland GmbH, 65926 FRANKFURT AM MAIN AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (DE). BEIL, Christian; c/o sanofi-aventis Deutschland CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — GmbH, 65926 FRANKFURT AM MAIN (DE). BENIN- DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, GA, Jochen; c/o sanofi-aventis Deutschland GmbH, 65926 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = Title: BISPECIFIC ANTIBODY-LIKE BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND CD123 (54) = = A B = r1 I g2 , 3i = KD .azr IVO = _ 245 i = 190 kl 135 100 ,„,, w 1 = 80 *ft Mil — = '4' = 58 2,1,0 1 46 ,.„„ . 32 . at I i wen = = _ = 25 lis i . Ate toT 22 ..., 17 .... R iu 11 .-44 — ,—, FIG.2 © 7r M 11 in (57) : The present invention concerns antibody-like binding protein specifically binding to CD3 and CD123. The invention also C ,—, - --- GC relates to pharmaceutical compositions comprising said antibody-like binding protein and the use of said pharmaceutical compositions , 1 and antibody-like binding protein to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising 0 a sequence encoding said antibody-like binding protein. ei C [Continued on next page] WO 2018/015340 Al MIDEDIMOMOIDEIREIDIONIM11011100H0110EVOIS KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201900400QA 2016-07-18 2017-07-17 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 SG11201900400QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305923 2016-07-18
PCT/EP2017/068020 WO2018015340A1 (en) 2016-07-18 2017-07-17 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Publications (1)

Publication Number Publication Date
SG11201900400QA true SG11201900400QA (en) 2019-02-27

Family

ID=56507555

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900400QA SG11201900400QA (en) 2016-07-18 2017-07-17 Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Country Status (24)

Country Link
US (1) US20190241657A1 (en)
EP (1) EP3484924A1 (en)
JP (2) JP7071329B2 (en)
KR (1) KR20190028771A (en)
CN (1) CN109715665A (en)
AR (1) AR109264A1 (en)
AU (1) AU2017299125A1 (en)
BR (1) BR112019000770A2 (en)
CA (1) CA3030943A1 (en)
CL (1) CL2019000119A1 (en)
CO (1) CO2019001367A2 (en)
CR (1) CR20190072A (en)
DO (1) DOP2019000011A (en)
EA (1) EA201990321A1 (en)
EC (1) ECSP19011185A (en)
IL (1) IL264248A (en)
MA (1) MA45680A (en)
MX (1) MX2019000844A (en)
PE (1) PE20190514A1 (en)
PH (1) PH12019500122A1 (en)
SG (1) SG11201900400QA (en)
TN (1) TN2019000015A1 (en)
TW (1) TWI790206B (en)
WO (1) WO2018015340A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000275A1 (en) 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
JO3792B1 (en) 2015-07-31 2021-01-31 Amgen Res Munich Gmbh Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Antibody constructs for msln and cd3
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
CA3118081A1 (en) * 2018-10-30 2020-05-07 Macrogenics, Inc. Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
BR112021017801A2 (en) * 2019-03-11 2022-01-18 Janssen Biotech Inc Bispecific anti-vbeta17/anti-cd123 antibodies
CN111171155B (en) * 2020-02-05 2021-02-19 北京智仁美博生物科技有限公司 anti-CD 3 and CD123 bispecific antibodies and uses thereof
TW202200619A (en) * 2020-03-17 2022-01-01 美商西雅圖免疫公司 Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof
JP2024506831A (en) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for treating cytokine release syndrome
CN113368232B (en) * 2021-06-02 2022-08-26 上海交通大学 Multispecific antigen binding proteins and uses thereof
CA3224408A1 (en) * 2021-08-06 2023-02-09 Rosalba LEPORE Discernible cell surface protein variants for use in cell therapy
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
EP0497883B1 (en) 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
AU9166691A (en) 1990-12-20 1992-07-22 Ixsys, Inc. Optimization of binding proteins
EP0689601B1 (en) 1993-02-22 2006-10-04 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (en) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition for the production of therapeutic products in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3946256B2 (en) 1995-09-11 2007-07-18 協和醗酵工業株式会社 Antibody to human interleukin 5 receptor α chain
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
DE19721700C1 (en) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutant OKT3 antibody
DE69909459T2 (en) 1998-04-21 2004-05-27 Micromet Ag CD19XCD3 SPECIFIC POLYPEPTIDES AND THEIR USE
US6733743B2 (en) 2000-03-06 2004-05-11 University Of Kentucky Research Foundation Methods to impair hematologic cancer progenitor cells and compounds related thereto
CN111909273A (en) 2007-08-29 2020-11-10 塞诺菲-安万特股份有限公司 Humanized anti-CXCR 5 antibodies, derivatives thereof and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101837053B1 (en) * 2008-10-01 2018-03-12 암젠 리서치 (뮌헨) 게엠베하 Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibody
TWI622597B (en) 2011-03-28 2018-05-01 賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
MX352101B (en) 2011-08-23 2017-11-08 Roche Glycart Ag Bispecific t cell activating antigen binding molecules.
HUE059815T2 (en) * 2012-05-18 2022-12-28 Aptevo Res & Development Llc Bispecific scfv immunofusion (bif) binding to cd123 and cd3
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
BR112016009617A2 (en) * 2013-12-10 2017-09-19 Hoffmann La Roche USE OF A CONJUGATE OF A BINDER DOMAIN AND METHOD FOR TARGETED DELIVERY OF A POLYPEPTIDE
WO2016036937A1 (en) * 2014-09-05 2016-03-10 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
RS62332B1 (en) * 2014-11-26 2021-10-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd20
TN2017000275A1 (en) * 2015-01-23 2018-10-19 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123

Also Published As

Publication number Publication date
TN2019000015A1 (en) 2020-07-15
CR20190072A (en) 2019-06-25
AR109264A1 (en) 2018-11-14
CA3030943A1 (en) 2018-01-25
US20190241657A1 (en) 2019-08-08
BR112019000770A2 (en) 2019-07-02
MX2019000844A (en) 2019-07-04
EP3484924A1 (en) 2019-05-22
AU2017299125A1 (en) 2019-03-07
PH12019500122A1 (en) 2019-04-15
JP2019531701A (en) 2019-11-07
DOP2019000011A (en) 2019-05-15
PE20190514A1 (en) 2019-04-10
EA201990321A1 (en) 2019-06-28
JP2022105138A (en) 2022-07-12
CN109715665A (en) 2019-05-03
ECSP19011185A (en) 2019-02-28
IL264248A (en) 2019-02-28
TW201811830A (en) 2018-04-01
CO2019001367A2 (en) 2019-02-19
CL2019000119A1 (en) 2019-06-14
JP7071329B2 (en) 2022-05-18
MA45680A (en) 2019-05-22
WO2018015340A1 (en) 2018-01-25
KR20190028771A (en) 2019-03-19
TWI790206B (en) 2023-01-21

Similar Documents

Publication Publication Date Title
SG11201900400QA (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811115TA (en) Optimized mini-dystrophin genes and expression cassettes and their use
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201805268XA (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201408679XA (en) Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201408746XA (en) Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201909520VA (en) Rna for treatment of autoimmune diseases
SG11201805497QA (en) Mutated truncated von willebrand factor
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201803642WA (en) Bacteria-based protein delivery
SG11202000077RA (en) Methods of treating behavior alterations